title: MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy.
abstract: The MIB-1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB-1 labeling index at the time of diagnosis, in 98 patients with follicular lymphoma (FL) grade 1-3b who were treated uniformly with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy. The 5-year progression-free survival (PFS) for an MIB-1 labeling index of ≥10% (n = 60) and <10% (n = 38) was 35% and 61%, respectively (P = 0.015). The 5-year overall survival (OS) for an MIB-1 labeling index of ≥10% and <10% was 77% and 92%, respectively (P = 0.025). Pathological grading was not correlated with PFS or OS. In multivariate analysis, an MIB-1 labeling index of ≥10% was independently associated with poor PFS and OS. In conclusion, an MIB-1 labeling index of 10% is a useful cut-off level for predicting the prognosis of patients with FL.
authors.affiliation: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Eri
authors.initials: E
authors.lastname: Yamamoto
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Seiji
authors.initials: S
authors.lastname: Sakata
authors.forename: Naoko
authors.initials: N
authors.lastname: Tsuyama
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Kazuho
authors.initials: K
authors.lastname: Miyashita
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Tachibana
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Takasaki
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Tanaka
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hashimoto
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Koharazawa
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Harano
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D000069283:Rituximab; D013534:Survival; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019394:Ki-67 Antigen; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone